- Home
- THQ vs CDNA Comparison
THQ vs CDNA Comparison
Compare THQ & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | THQ | CDNA |
|---|---|---|
| Founded | 2014 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 753.1M | 712.2M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | THQ | CDNA |
|---|---|---|
| Price | $18.94 | $19.87 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $26.00 |
| AVG Volume (30 Days) | 158.9K | ★ 816.3K |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 7.53% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.22 |
| Revenue | N/A | ★ $357,998,000.00 |
| Revenue This Year | N/A | $14.11 |
| Revenue Next Year | N/A | $12.00 |
| P/E Ratio | ★ N/A | $16.92 |
| Revenue Growth | N/A | ★ 14.46 |
| 52 Week Low | $15.29 | $10.96 |
| 52 Week High | $20.38 | $25.95 |
Technical Indicators
Market Signals| Indicator | THQ | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 62.05 | 66.40 |
| Support Level | $18.30 | $18.36 |
| Resistance Level | $18.94 | $19.95 |
| Average True Range (ATR) | 0.28 | 0.87 |
| MACD | -0.02 | 0.16 |
| Stochastic Oscillator | 56.93 | 75.85 |
Price Performance
Historical ComparisonAbout THQ abrdn Healthcare Opportunities Fund Shares of Beneficial Interest
abrdn Healthcare Opportunities Fund is a non-diversified closed-end fund in the United States. The fund's investment objective is to seek current income and long-term capital appreciation through investments in U.S. and non-U.S. companies.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.